South Shore Health Center for Wound Healing, Weymouth, Massachusetts, USA.
Brown University School of Medicine, Providence, Rhode Island, USA.
Wound Repair Regen. 2021 Jan;29(1):60-69. doi: 10.1111/wrr.12872. Epub 2020 Nov 5.
The 2006 U.S. Food and Drug Administration Guidance for Industry emphasizes wound closure as the primary outcome for clinical trials in wound healing. Wound care professionals understand that complete wound healing is not always achievable when evaluating new treatments. FDA, Association for the Advancement of Wound Care, and Wound Healing Society are working collaboratively to identify scientifically achievable, clinically relevant, and patient-centered endpoints with sufficient support to serve as primary outcomes for clinical trials. The Opinion Survey from People with Wounds presented here addresses an important but understudied issue: the gap between clinician, healthcare insurance companies, government agencies, and patient perspectives regarding clinically meaningful and scientifically achievable primary endpoints for wound care. The survey, adapted from the clinician survey with adjustment for health literacy, was pilot tested and revised based on a limited number of patients in a single clinic. After central IRB approval, the on-line survey was administered in English and Spanish and submitted anonymously to a server with the cooperation of multiple wound clinics and societies. Four hundred and thirty-eight patients and caregivers from across the United States responded over a 10-month period. Based on this survey, the most valuable clinical endpoints were reduced infection, recurrence, and amputation. The most valuable quality of life outcomes were increased independence, reduced social isolation, and pain. The top five endpoints in terms of usefulness for measuring clinical trial success were time to heal, wound size, infection, recurrence, and pain. Narrative responses from wound patients emphasized the inability to perform activities of daily living and pain as major factors that impacted their daily lives. Engagement of patients in clinical trials and evaluation of potential treatments is critical to improving wound care. This survey provides insight into the needs of patients with wounds and provides a roadmap for structuring future clinical trials to better meet those needs.
2006 年美国食品和药物管理局(FDA)发布的行业指南强调,伤口闭合是临床试验中伤口愈合的主要终点。伤口护理专业人员明白,在评估新的治疗方法时,并非总能实现完全的伤口愈合。FDA、伤口护理促进协会(Association for the Advancement of Wound Care)和伤口愈合协会(Wound Healing Society)正在合作,以确定具有科学可行性、临床相关性和以患者为中心的终点,这些终点需要有足够的支持,以作为临床试验的主要终点。这里呈现的《有伤口的人意见调查》(Opinion Survey from People with Wounds)探讨了一个重要但研究不足的问题:即临床医生、医疗保险公司、政府机构和患者对伤口护理具有临床意义和科学可行性的主要终点的看法之间存在差距。该调查是对临床医生调查的改编,针对健康素养进行了调整,并在一家诊所的少数患者中进行了试点测试和修订。在获得中央机构审查委员会(IRB)批准后,该在线调查以英文和西班牙文进行,并在多个伤口诊所和协会的合作下匿名提交到一个服务器。来自美国各地的 438 名患者及其护理人员在 10 个月的时间内做出了回应。基于这项调查,最有价值的临床终点是降低感染、复发和截肢的风险。最有价值的生活质量结果是提高独立性、减少社会孤立和减轻疼痛。就衡量临床试验成功的有用性而言,排名前五的终点是愈合时间、伤口大小、感染、复发和疼痛。来自伤口患者的叙述性回复强调了无法进行日常生活活动和疼痛是影响他们日常生活的主要因素。让患者参与临床试验和评估潜在的治疗方法对于改善伤口护理至关重要。本调查深入了解了伤口患者的需求,并为未来临床试验的结构提供了蓝图,以更好地满足这些需求。